Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.

The main offer period of the Offer ended on 12 October 2026, at 4:00 p.m. Swiss time. According to the provisional interim result as published by Samsung Peptide,

Samsung Peptide and the persons acting in concert with it hold a total of 29,123,892 PolyPeptide shares, representing 87.92% of PolyPeptide’s issued share capital and voting rights. By the end of the main offer period, 29,014,418 PolyPeptide shares had been tendered into the offer. This corresponds to 87.59% of the issued share capital and voting rights of PolyPeptide and 87.88% of all shares to which the offer relates.

The interim result that has been published today by Samsung Peptide is provisional and is available at https://samsungbiologics.com/offer. The definitive interim result is expected to be published on 16 October 2026. The provisional and the definitive end result of the Offer will be published after the end of the additional acceptance period (see below).

According to the provisional interim result published by Samsung Peptide, the offer condition regarding the minimum acceptance rate, as set out in section B.7.1(a) of the offer prospectus dated 31 August 2026, has been satisfied, subject to confirmation of the preliminary figures in the definitive interim result. In addition, the offer condition concerning the absence of a material adverse effect under section B.7.1(d) of the offer prospectus has also been fulfilled.

The Offer remains subject to customary offer conditions, including the receipt of regulatory approvals in certain jurisdictions as well as the removal of the transfer restrictions and voting limitations from PolyPeptide’s articles of association and the election of the persons nominated by Samsung Biologics to the board of directors of PolyPeptide by resolution of an extraordinary general meeting of PolyPeptide. PolyPeptide has invited for an extraordinary general meeting to be held on 26 October 2026 to resolve on these matters.

According to the provisional interim result as published by Samsung Peptide, if the Offer is declared successful (zustande gekommen) in the definitive notice of the interim result, the additional acceptance period of ten (10) trading days for the subsequent acceptance of the Offer will commence on 19 October 2026 and end on 30 October 2026, 4:00 p.m. Swiss time, in accordance with section B.6 (Additional Acceptance Period) of the Offer Prospectus.

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com investorrelations@polypeptide.com
T: +41 43 502 0580